Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Probing of breast cancer using a combination of plasma and urinary circulating cell-free DNA.

Bioscience reports - 27 Nov 2020

Zuo Zhigang, Tang Jiying, Cai Xiaojun, Ke Feng, Shi Zhenzong

Abstract excerpt

Monitoring of early-stage breast cancer is critical in promptly addressing disease relapse. Circulating cell-free DNA provides a minimally invasive and sensitive means to probing the disease. In a longitudinal analysis of 250 patients with early breast cancer, we compared the circulating cell-free DNA recovered from both plasma and urine specimens. For comparison, 50 healthy controls were also recruited. Specific...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Circulating Tumor DNA
Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Longitudinal Studies

Share to Neoplasm Recurrence, Local

Share to Neoplasm Staging

Share to Predictive Value of Tests

Share to Reproducibility of Results

Share to Risk Assessment

Source

Open in PubMed Open full text

Identifiers

PMID: 33044511
DOI: 10.1042/BSR20194306
PMCID: PMC7610146

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Probing of breast cancer using a combination of plasma and urinary circulating cell-free DNA.PMID 33044511Read ↗

Precision Medicine for Breast Cancer Utilizing Circulating Tumor DNA: It Is in the Blood.Semantic proximity Read ↗

Circulating Cell-Free DNA in Breast Cancer: Searching for Hidden Information towards Precision MedicineSemantic proximity Read ↗

Circulating Tumor DNA in Breast Cancer: Current and Future Applications.Semantic proximity Read ↗

Circulating tumor cells and circulating tumor DNA in breast cancer diagnosis and monitoring.Semantic proximity Read ↗

The applications of plasma cell-free DNA in cancer detection: Implications in the management of breast cancer patients.Semantic proximity Read ↗

Treatment and relapse in breast cancer show significant correlations to noninvasive testing using urinary and plasma DNA.Semantic proximity Read ↗

The use of cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) to guide treatment selection in metastatic breast cancer.Semantic proximity Read ↗

Clinical application of circulating tumor DNA in breast cancer.Semantic proximity Read ↗

Circulating DNA as biomarker in breast cancer.Semantic proximity Read ↗

The role of ctDNA detection and the potential of the liquid biopsy for breast cancer monitoring.Semantic proximity Read ↗

Cell‐free circulating tumour DNA as a liquid biopsy in breast cancerSemantic proximity Read ↗

Circulating non-coding RNAs as a diagnostic and management biomarker for breast cancer: current insights.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.